Please assess the completion status of the following clinical trial:

Trial Title: Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided informed consent.~* Fasting LDL-C ≥ 75 mg/dL and meeting the following LDL-C values on background lipid-lowering therapy:~  * \< 100 mg/dL for subjects with diagnosed coronary heart disease (CHD) or CHD risk equivalent~ * \< 130 mg/dL for subjects without diagnosed CHD or CHD risk equivalent~ * OR on maximal background lipid-lowering therapy defined as atorvastatin 80 mg PO QD and ezetimibe 10 mg PO QD~* Fasting triglycerides ≤ 400 mg/dL~Exclusion Criteria:~* New York Heart Association (NYHA) II-IV heart failure, or last known left ventricular ejection fraction \< 30%~* Uncontrolled cardiac arrhythmia~* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization, type 1 diabetes, newly diagnosed or poorly controlled type 2 diabetes~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Evolocumab (Type: EXPERIMENTAL): Participants received evolocumab 420 mg subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).